Amylyx, Alto Neuro, and Eli Lilly for the Oscars


Amylyx Pharmaceuticals announced that their ALS treatment, Relyvrio, failed to provide any benefit in a large clinical trial, leading to consideration of withdrawing the medicine. The FDA called for a meeting to discuss Eli Lilly’s Alzheimer’s drug, donanemab, despite successful trial results. President Biden’s proposal to expand Medicare price negotiation in his State of the Union address indicates ongoing scrutiny of the pharmaceutical industry. Other topics include the challenges of accessing addiction treatments, small companies competing in obesity, and the impact of psychiatric drug research. Additionally, Eli Lilly launched an anti-vanity ad campaign for their diabetes and obesity drugs ahead of the Oscars.

Source link

error: Content is protected !!